Ebo­la vac­cine built on same tech­nol­o­gy as Covid-19 jab from J&J shows long-last­ing suc­cess

Just weeks af­ter a J&J can­di­date failed its first tri­al in an ef­fort to build a vac­cine against HIV, that same vac­cine tech­nol­o­gy scored the com­pa­ny a vic­to­ry in the fight against a virus that has emerged yet again, and threat­ens to cause hav­oc in Africa if left unchecked along­side Covid-19.

A two-dose vac­cine reg­i­men from J&J to fight Ebo­la was long-last­ing dur­ing tri­als in adults and chil­dren, the com­pa­ny said Mon­day, as the im­mune re­sponse lasts in adults for at least two years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER